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Signal transducer and activator of transcription 3 (STAT3) is a
multifunctional protein that participates in signaling pathways
initiated by various growth factors and cytokines. It exists in
multiple forms including those phosphorylated on Tyr705 (pYSTAT3)
or Ser727 (pSSTAT3) as well as the unphosphorylated protein
(USTAT3). In addition to the canonical transcriptional regulatory role
of pYSTAT3, both USTAT3 and pSSTAT3 function as transcriptional
regulators by binding to distinct promoter sites and play signaling
roles in the cytosol or mitochondria. The roles of each STAT3 species
in different biological processes have not been readily amenable
to investigation, however. We have now prepared an intrabody
that binds specifically and with high affinity to the tyrosine-
phosphorylated site of pYSTAT3. Adenovirus-mediated expression
of the intrabody in HepG2 cells as well as mouse liver blocked both
the accumulation of pYSTAT3 in the nucleus and the production of
acute phase response proteins induced by interleukin-6. Intrabody
expression did not affect the overall accumulation of pSSTAT3 in-
duced by interleukin-6 or phorbol 12-myristate 13-acetate (PMA),
the PMA-induced expression of the c-Fos gene, or the PMA-induced
accumulation of pSSTAT3 specifically in mitochondria. In addition,
it had no effect on interleukin-6–induced expression of the gene for
IFN regulatory factor 1, a downstream target of STAT1. Our results
suggest that the engineered intrabody is able to block specifically
the downstream effects of pYSTAT3 without influencing those of
pSSTAT3, demonstrating the potential of intrabodies as tools to
dissect the cellular functions of specific modified forms of proteins
that exist as multiple species.
Signal transducer and activator of transcription 3 (STAT3) is amember of the STAT family of transcription factors (STAT1
to STAT6) and was originally identified as an acute phase response
(APR) factor that is activated by interleukin (IL)-6. STAT3 regu-
lates the expression of a variety of genes in response to its activa-
tion by IL-6 family cytokines, peptide growth factors, interferons
(IFNs), and oncoproteins. As with other STAT proteins, the
transactivation function of STAT3 is activated when a critical
tyrosine residue (Tyr705 in STAT3) is phosphorylated, which
results in dimerization of the protein through reciprocal inter-
actions between the phosphotyrosine and a Src homology 2
(SH2) domain. The tyrosine-phosphorylated form of STAT3
(pYSTAT3) translocates from the cytosol to the nucleus, where it
binds to the IFN-γ–activated sequence (GAS) in target promoters
and thereby activates transcription (1–4).
Most STAT proteins also contain a serine phosphorylation site
(Ser727 in STAT3). Although the serine-phosphorylated form of
STAT3 (pSSTAT3) also participates in transcriptional regula-
tion, such phosphorylation can have a positive or negative effect
on transactivation activity (5). The ultimate biological outcome
of pSSTAT3 signaling appears to depend on the extracellular
stimulus, gene promoter, cell type, and activation status of the
cell (5). Whereas all of the cell surface receptors known to increase
pYSTAT3 abundance also increase the amount of pSSTAT3,
pSSTAT3 is also generated in the absence of pYSTAT3 in re-
sponse to several stimuli (5). Moreover, pSSTAT3 is also found
in mitochondria and regulates mitochondrial respiration (6–8).
STAT3 is also acetylated on a lysine residue, with this modi-
fication being essential for the formation of stable dimers (3).
A feature of STAT3 that distinguishes it from other STAT pro-
teins is its prominent nuclear localization in the absence of its
tyrosine phosphorylation. Unphosphorylated STAT3 (USTAT3)
thus shuttles between the cytoplasmic and nuclear compartments,
binds to DNA, and functions as a transcriptional activator and a
chromatin or genomic organizer (9, 10).
The biological effects of STAT3 are diverse, likely reflecting
its activation by a wide range of cytokines, growth factors, and
oncoproteins as well as the actions of variously modified STAT3
species in the nucleus, cytosol, and mitochondria. The deciphering
of such diverse STAT3 functions will require dissection of the role
of each covalently modified form of STAT3. Intrabodies, which are
intracellular, recombinant, single-chain antibody fragments that
comprise the heavy (VH) and light (VL) antigen binding domains
connected by a linker, are an attractive option for neutralization
of the function of a protein posttranslationally modified at a spe-
cific site, given the possibility of developing high-affinity binders to
the modified site and their intrinsic specificity.
We have now generated an intrabody that binds specifically to
the tyrosine-phosphorylated sequence of pYSTAT3 and have
studied the effects of its expression on downstream signaling in
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HepG2 human hepatoma cells stimulated with IL-6 and in
mouse liver stimulated with IL-6 or lipopolysaccharides (LPS).
Adenovirus-mediated expression of the intrabody blocked sig-
naling downstream of pYSTAT3 but not that downstream of
pYSTAT1. Intrabody expression affected neither the abundance
of nor signaling by pSSTAT3. Comparison of the effects of
intrabody expression with those of STAT3 knockdown by RNA
interference (RNAi) or STAT3 inhibition with a chemical agent
revealed the effectiveness and benefits of intrabodies for char-
acterization of a protein like STAT3 that has multiple functions
dependent on different types of covalent modification.
Results
Generation of an Intrabody That Binds Specifically to the Tyrosine-
Phosphorylation Site of pYSTAT3. A rabbit–human chimeric anti-
gen-binding fragment (Fab) phagemid library was prepared with
mRNA isolated from the bone marrow and spleen of rabbits
immunized with an 11-amino acid peptide (PGSAAPpYLKTK,
designated the pYSTAT3 peptide) that corresponds to the sequence
surrounding the phosphorylated Tyr705 residue of STAT3. The
presence of pYSTAT3-reactive antibodies in the serum of im-
munized rabbits was detected by immunoblot analysis of IL-6–
stimulated HepG2 cells (Fig. S1A). To select for specific binders
of pYSTAT3, we subjected phage to four rounds of panning with
the pYSTAT3 peptide conjugated to BSA and immobilized on
magnetic beads. Fab fragments (Fig. S1B) expressed in the
Escherichia coli system from 10 randomly selected clones were
tested for their reactivity with the pYSTAT3 peptide with the use
of an ELISA. All of the selected Fabs were found to bind to the
BSA-conjugated pYSTAT3 peptide but not to the corresponding
unphosphorylated STAT3 peptide (Fig. S1C). Sequencing anal-
ysis revealed that 4 of the 10 clones were highly related to each
other, differing by only seven amino acid residues in their light-
chain complementarity-determining regions (LCDRs), with
all amino acid residues being identical in their heavy-chain
complementarity-determining regions (HCDRs) (Fig. S1D). The
remaining 6 clones differed from each other in all CDRs in-
cluding HCDR3 (Fig. S1D), a key region for antigen binding.
We converted the Fab phage clones to a single-chain variable
fragment (scFv) form, in which VH and VL domains of each Fab
are joined via a flexible polypeptide linker (GGSSRSSSSGG-
GGSGGGG), and we then fused scFv to the human fragment
crystallizable (Fc) region to generate a scFv–Fc fusion protein.
Each scFv–Fc fusion protein was also targeted for secretion by
the addition of a mouse Ig kappa (Igκ) leader sequence to the
NH2 terminus, thus allowing the minibodies to be purified from
culture supernatants. The fusion antibody derived from clone 17
(Fig. S2 A and B), one of the four closely related clones, was
expressed at a much higher level compared with those derived
from the other clones, and we therefore focused on the char-
acterization of this fusion protein. Surface plasmon resonance
analysis with various concentrations of scFv–Fc17 fusion protein
(50–200 nM) and a fixed amount of BSA-conjugated pYSTAT3
peptide revealed that the fusion protein bound to the pYSTAT3
peptide with high affinity [dissociation constant (Kd) = 76 pM;
association rate constant (kon) = 1.37 × 10
4 M–1·s–1; and dissociation
rate constant (koff) = 1.05 × 10
−5·s–1)] (Fig. S1E).
Immunoblot analysis indicated that STAT3 was recognized by
scFv–Fc17 fusion protein in IL-6–stimulated HepG2 cells but not
in unstimulated cells (Fig. S2C). HepG2 cell lysates were then
subjected to immunoprecipitation with the fusion protein, and
the resulting precipitates were subjected to immunoblot analysis
with commercial antibodies to pYSTAT3, STAT3, and phos-
photyrosine (Fig. S2D). A STAT3 band was detected by all three
antibodies only in the immunoprecipitates prepared from IL-6–
stimulated cells, and no other bands were detected by the anti-
bodies to STAT3 or to phosphotyrosine. These results thus in-
dicated that scFv–Fc17 fusion protein recognizes pYSTAT3
selectively over USTAT3 and that it precipitates only pYSTAT3
and not other tyrosine-phosphorylated proteins, despite the fact
that multiple proteins are phosphorylated on tyrosine in re-
sponse to stimulation with IL-6 (11).
To study the effects of intracellular expression of a pYSTAT3-
specific antibody, we infected HepG2 cells with an adenovirus
encoding the scFv region (VL-linker-VH) of scFv–Fc17 fusion
protein fused to green fluorescent protein (GFP), with the fusion
protein being designated intrabody 17 (Fig. 1A). The abundance
of pYSTAT3 in HepG2 cells maintained in serum-free medium
was increased in proportion to the amount of the infecting GFP–
scFv17 virus, whereas it was unaffected by infection with an ade-
novirus encoding GFP alone (Fig. 1B). These results indicated
that tyrosine phosphorylation of STAT3 occurs in unstimu-
lated HepG2 cells and that tight binding of GFP–scFv17 to the
nascent pYSTAT3 molecules and their consequent protection
from protein tyrosine phosphatases results in the accumula-
tion of pYSTAT3 in a manner dependent on GFP–scFv17 con-
centration. IL-6 stimulation also induced the accumulation of
pYSTAT3 to much higher levels in cells expressing GFP–
scFv17 than in those expressing GFP (Fig. 1C). In addition, IL-
6 increased the abundance of STAT3 phosphorylated on Ser727
(pSSTAT3), but the expression of GFP–scFv17 had no effect on
pSSTAT3 accumulation (Fig. 1C). This was confirmed after
fractionation of IL-6–stimulated HepG2 cell lysates on longer
SDS gels, which yielded two bands, the lower band containing
STAT3 proteins phosphorylated only on Tyr705 and the upper
Fig. 1. Effect of GFP–scFv17 (intrabody 17) expression on the abundance of
pYSTAT3 and pSSTAT3 and the selective binding of intrabody 17 to pYSTAT3
within HepG2 cells. (A) Domain organization of GFP–scFv17. (B) Effect of
GFP–scFv17 expression on pYSTAT3 abundance in HepG2 cells. Cells infected
with recombinant adenoviruses encoding GFP or GFP–scFv17 at various
multiplicities of infection [MOI: 0, 25, or 100 plaque-forming units (pfu) per
cell] were maintained in serum-free medium for 24 h, lysed, and subjected to
immunoblot analysis with antibodies to pYSTAT3, STAT3, GFP, and β-actin
(loading control). The positions of GFP–scFv17 and GFP are indicated. (C)
Effect of GFP–scFv17 expression on the abundance of pYSTAT3 or pSSTAT3
in IL-6–stimulated HepG2 cells. Cells infected with adenoviruses for GFP (100
pfu per cell) or for GFP–scFv17 (0, 25, 50, or 100 pfu per cell) were incubated
with or without IL-6 (50 ng/mL) for 30 min, after which cell lysates were
subjected to immunoblot analysis with antibodies to the indicated proteins.
Some lanes are spliced together from the same immunoblot; these alter-
ations are indicated by a vertical line between the lanes. (D and E) Selective
binding of GFP–scFv17 to pYSTAT3 inside of HepG2 cells. Cells infected with
adenoviruses for GFP or GFP–scFv17 (100 pfu per cell) were incubated in the
absence or presence of IL-6 (50 ng/mL) for 30 min, after which cell lysates
were directly subjected to immunoblot analysis with antibodies to pYSTAT3
or to STAT3 (D), or they were first subjected to immunoprecipitation with
antibodies to GFP and the resulting precipitates were subjected to immu-
noblot analysis with antibodies to pYSTAT3, STAT3, or GFP (E). The asterisk
indicates nonspecific binding.
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band containing STAT3 proteins phosphorylated only on Ser727
or phosphorylated on both Tyr705 and Ser727 (Fig. S3). The in-
tensity of the upper bands was not significantly affected by
GFP–scFv17 expression (Fig. S3).
To confirm the specific binding of GFP–scFv17 to pYSTAT3,
we subjected lysates of IL-6–stimulated or -unstimulated HepG2
cells expressing GFP or GFP–scFv17 to immunoprecipitation
with antibodies to GFP. The resulting immunoprecipitates
were then subjected to immunoblot analysis with antibodies to
pYSTAT3, STAT3, or GFP. Although immunoblot analysis of
cell lysates indicated that the abundance of pYSTAT3 in IL-6–
stimulated GFP-expressing cells was similar to that in unstimu-
lated GFP–scFv17-expressing cells (Fig. 1D), bands immunore-
active with anti-pYSTAT3 and with anti-STAT3 were detected
in the immunoprecipitates from the latter cells but not in those
from the former (Fig. 1E). In addition, the intensity of these
immunoreactive bands was greater for the immunoprecipitates
from IL-6–stimulated GFP–scFv17-expressing cells than for
those from unstimulated GFP–scFv17-expressing cells (Fig. 1E).
These results suggested that GFP–scFv17 molecules are suffi-
ciently expressed inside the cells to forms a stable complex with
pYSTAT3 even after the stimulation with IL-6.
In HepG2 cells, IFN-γ induces tyrosine phosphorylation of
STAT1 but not that of STAT3, whereas IL-6 induces tyrosine
phosphorylation of STAT3 and to a much lesser extent that of
STAT1 (12, 13). Immunoblot analysis of HepG2 cells stimulated
with IFN-γ or IL-6 revealed that the commercial antibodies to
pYSTAT3 recognized pYSTAT3 but not pYSTAT1 (Fig. S4A).
Whereas the abundance of pYSTAT3 was increased by GFP–
scFv17 expression in cells incubated with or without IL-6, GFP–
scFv17 expression had no effect on the abundance of pYSTAT1
(Fig. S4B). Furthermore, expression of GFP–scFv17 had no
effect on expression of the gene for IFN regulatory factor 1
(IRF1), a downstream target of STAT1, in HepG2 cells in-
cubated with or without IL-6 (Fig. S4C). These results suggested
that intrabody 17 binds pYSTAY3 but not pYSTAT1.
Furthermore, the ability of GFP–scFv17 to recognize pYSTAT3
selectively over pYSTAT2 was demonstrated in HeLa cells stimu-
lated with IFN-α (Fig. S5A), over pYSTAT4 in NK92 cells stimu-
lated with IL-12 (Fig. S5B), over STAT5 in A431 cells stimulated
with EGF (Fig. S5C), and over pYSTAT6 in HeLa cells stimulated
with IL-4 (Fig. S5D). In all of these experiments, pYSTAT3
abundance was increased following GFP–scFv17 expression with
or without stimulant, whereas GFP–scFv17 expression had no
effect on the abundance of the other pYSTATs.
Intrabody 17 Blocks the Nuclear Translocation of pYSTAT3 and Expression
of APR Proteins in HepG2 Cells Stimulated with IL-6 as Well as in Mouse
Liver Stimulated with IL-6 or LPS. The effect of intrabody expres-
sion on the IL-6–induced nuclear translocation of STAT3 in
HepG2 cells was examined by immunofluorescence analysis
with antibodies to STAT3 or pYSTAT3. For unstimulated cells
expressing either GFP or GFP–scFv17, most immune reactivity for
anti-STAT3 was detected in the cytosol, with only a small amount
apparent in the nucleus (Fig. 2A). Stimulation with IL-6 resulted in
a marked increase in anti-STAT3 immunoreactivity in the nu-
cleus in GFP-expressing cells but not in GFP–scFv17-expressing
cells (Fig. 2A). Immunoreactivity for anti-pYSTAT3 was
detected predominantly in the nucleus of IL-6–stimulated
GFP-expressing cells but was apparent in the cytosol of unsti-
mulated or IL-6–stimulated GFP–scFv17-expressing cells (Fig. 2B).
We also examined the intracellular distribution of STAT3 and
pYSTAT3 by immunoblot analysis of whole cell lysates as well as of
separated nuclear and cytosolic fractions (Fig. 2C). In agreement
with the immunofluorescence results, pYSTAT3 generated in GFP-
expressing cells in response to IL-6 stimulation was found exclusively
Fig. 2. GFP–scFv17 blocks the nuclear translocation of
pYSTAT3 and expression of APR proteins in HepG2 cells
stimulated with IL-6. (A and B) HepG2 cells infected for
24 h with adenoviruses encoding GFP or GFP–scFv17 (50
pfu per cell) were incubated in the absence or presence
of IL-6 (100 ng/mL) for 30 min and then subjected to
immunofluorescence staining with antibodies to STAT3
(A) or with those to pYSTAT3 (B). Nuclei were also
stained with 4′,6-diamidino-2-phenylindole (DAPI). (Scale
bars, 10 μm.) (C) Whole cell lysates, cytosolic, and nuclear
fractions prepared from HepG2 cells infected and stim-
ulated as in A and B were subjected toimmunoblot
analysis with antibodies to the indicated proteins. HSP90
and lamin B were examined as cytosolic and nuclear
markers, respectively. (D) HepG2 cells infected as in A and
B were incubated in the absence or presence of IL-6 (50
ng/mL) for 30 min, after which cell lysates were subjected
to immunoblot analysis with antibodies to pYSTAT3,
pSSTAT3, or STAT3 or with those to haptoglobin (HapG),
fibrinogen, or β-actin, respectively. The two bands rec-
ognized by anti-HapG are the glycosylated and non-
glycosylated forms of the β-chain, and the two bands
recognized by antifibrinogen are the α- and β-chains.
Some lanes are spliced together from the same immu-
noblot; these alterations are indicated by a vertical line
between the lanes.
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in the nucleus, whereas that generated in IL-6–stimulated GFP–
scFv17-expressing cells remained in the cytosol. Immunoblot analysis
with antibodies to STAT3 revealed the IL-6–induced translocation of
STAT3 to the nucleus in GFP-expressing cells, whereas such trans-
location was not evident in GFP–scFv17-expressing cells. These
results thus suggested that intrabody 17 is an effective inhibitor of the
nuclear translocation of pYSTAT3.
IL-6 induces the production and secretion of APR proteins
such as haptoglobin, fibrinogen (α-, β-, and γ-chains), and serum
amyloid A proteins (SAA1–SAA3) in hepatocytes (14). The
binding of dimeric pYSTAT3 to GAS elements in the promoters
of such APR genes plays a key role in their transcriptional in-
duction by IL-6 (1). We next examined the effect of GFP–scFv17
expression on the IL-6–induced production of APR proteins in
HepG2 cells. Immunoblot analysis showed that IL-6 markedly
increased the production of haptoglobin (glycosylated and
unglycosylated β-chains) and fibrinogen (α- and β-chains) in
GFP-expressing cells (Fig. 2D). Expression of GFP–scFv17
almost completely blocked the induction of these proteins by
IL-6, whereas it increased the abundance of pYSTAT3 (Fig. 2D).
The induction of APR proteins by IL-6 was also blocked by
RNAi-mediated knockdown of STAT3 and by the chemical in-
hibitor stattic (Fig. S6), the latter of which selectively inhibits the
function of the SH2 domain of STAT3 (15). Expression of GFP–
scFv17 did not affect the serine phosphorylation of STAT3 in-
duced by IL-6 (Fig. 2D), whereas stattic did markedly inhibit this
effect of IL-6 (Fig. S6; see also Fig. 4C).
To test in vivo function of intrabody 17, adenoviruses encoding
GFP or GFP–scFv17 were injected through tail vein into mice to
achieve overexpression of intrabody 17 in the liver, and then
mice were further injected with IL-6 (Fig. 3). As observed in
HepG2 cells, the abundance of pYSTAT3 was increased by
GFP–scFv17 expression in the livers of mice injected with or
without IL-6, and the IL-6–induced nuclear translocation of
pYSTAT3 was prevented by GFP–scFv17 expression (Fig. 3A).
The expression of APR genes in the liver was measured in
mice injected with IL-6 for 0, 2, and 6 h by RT-PCR analyses of
the mRNAs for five APR genes: haptoglobin, fibrinogen, and
SAA1–SAA3. IL-6 induced increases in the expression of these
five genes in GFP-expressing mice (Fig. 3B). Expression of GFP–
scFv17 almost completely blocked the induction of these five
mRNAs (Fig. 3B).
In the liver, lipopolysacchride (LPS) activates the resident
macrophage Kupffer cells. Activated Kupffer cells produce pro-
inflammatory cytokines including IL-1β, IL-6, and tumor necrosis
factor α (TNFα) (16), which results in increased expression of
APR genes in liver. The effect of intrabody 17 on the expression of
APR genes in the liver was measured in GFP- or GFP–scFv17-
expressing mice after injection of LPS for 0, 8, and 16 h. As in the
case of IL-6 injection, LPS injection induced the nuclear trans-
location of pYSTA3 and the expression of the five APR genes
in GFP-expressing mice (Fig. 3 C and D), and the expression of
intrabody 17 blocked the LPS-induced nuclear translocation of
pYSTAT3 as well as the LPS-induced expression of hepatic
APR genes. We noted, however, that the pattern of APR down-
regulation resulting from the expression of the intrabody differs
significantly between IL-6– and LPS-injected mice. Whereas ex-
pression of all five hepatic APR genes was nearly completely
suppressed in IL-6–injected mice, their expression was inhibited
to widely varying extents in LPS-injected mice. Haptoglobin,
fibrinogen, and SAA1–SAA3 expression levels were inhibited
by ∼80%, ∼95%, ∼50%, ∼70%, and ∼15%, respectively, when
measured 8 h after LPS injection (Fig. 3D). These results provide
a striking illustration of the utility of the intrabody in evaluating
the differential impact of pYSTAT3 on the expression of distinct
genes in response to different stimuli.
Intrabody 17 Does Not Affect Induction of c-Fos Gene Expression by
PMA in HepG2 Cells. Transcription of the c-Fos gene is markedly
increased by phorbol 12-myristate 13-acetate (PMA) in HepG2 cells
(17). Treatment of HepG2 cells with PMA was also previously
shown to result in the accumulation of pSSTAT3 but not in that of
pYSTAT3 (17). The upstream regulatory region of the c-Fos gene
contains several regulatory sequences including the sis-inducible
element (SIE), which is thought to bind pSSTAT3 (17). The
SIE does not resemble a canonical STAT binding site, however,
and binding of pSSTAT3 to this element might require its in-
teraction with other nuclear proteins that are bound at the
gene promoter. Nevertheless, pSSTAT3 alone was found to be
sufficient to induce the accumulation of c-Fos mRNA (18).
PMA activates mitogen-activated protein kinsae (MAPK) signaling,
and PMA-induced pSSTAT3 accumulation is sensitive to the in-
hibition of MAPK kinase (MEK) by PD98059, suggesting that ex-
tracellular signal-related kinase (ERK), a member of the MAPK
family, is responsible for STAT3 phosphorylation on serine (17–19).
We investigated the effect of GFP–scFv17 on the PMA-induced
expression of the c-Fos gene in HepG2 cells. Consistent with
previous observations (17), PMA induced the accumulation of
pSSTAT3, but not that of pYSTAT3, and this pSSTAT3 accumu-
lation was inhibited by the MEK inhibitor PD98059 (Fig. 4A). The
increase in the abundance of pYSTAT3 induced by GFP–scFv17
expression was not affected by PMA alone or together with
Fig. 3. GFP–scFv17 blocks the IL-6– or LPS-induced expression of APR genes
in mice. (A and C) Adenoviruses encoding GFP or GFP–scFv17 were injected
into mice, and then mice were further injected with either IL-6 (A) or LPS (C),
and their livers were collected at indicated times. Whole liver lysates, cyto-
solic, and nuclear fractions prepared from the liver were subjected to im-
munoblot analysis with antibodies to pYSTAT3 or STAT3. (B and D) Total
RNA prepared from the liver treated as in A (B) or in C (D) was subjected to
quantitative RT-PCR analysis for determination of the relative amounts
of haptoglobin (HapG), fibrinogen, and SAA1–SAA3 mRNAs using specific
primers listed in Table S1 in GFP- (open bars) or GFP–scFv17 (solid bars)-
expressing mice. Data are means ± SD (n = 4).
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PD98059 (Fig. 4A). PMA induced a pronounced increase in the
amount of c-Fos mRNA in GFP-expressing HepG2 cells, and this
effect was largely abolished by PD98059 (Fig. 4B). Expression of
GFP–scFv17 inhibited the PMA-induced accumulation of c-Fos
mRNA by only ∼20% (Fig. 4B), with this effect likely being at-
tributable to the retention of some pSSTAT3 molecules in the
cytosol by GFP–scFv17 as a result of their also being phos-
phorylated on tyrosine. Stattic markedly inhibited PMA-induced
pSSTAT3 accumulation in both GFP- and GFP–scFv17-expressing
HepG2 cells, whereas GFP–scFv17 expression did not affect serine
phosphorylation of STAT3 (Fig. 4 B and C). In accordance with
these results, stattic inhibited the PMA-induced accumulation of
c-Fos mRNA by a greater extent, ∼40% in GFP-expressing cells
and ∼30% in GFP–scFv17-expressing cells, than did GFP–scFv17
expression (∼10% in these experiments) (Fig. 4D).
Intrabody 17 Does Not Affect the Abundance of Mitochondrial pSSTAT3
in PMA-Stimulated HepG2 Cells. In addition to its presence in the cy-
tosol and nucleus, STAT3 is also found in mitochondria of primary
tissues and cultured cells (6, 7). In mouse liver and heart, for
example, ∼10% of STAT3 is localized to mitochondria (6).
Mitochondrial STAT3 is required for optimal electron transport
function of complexes I and II, and it supports Ras-dependent
malignant transformation, with these mitochondrion-specific func-
tions being dependent on pSSTAT3 (6–8). We therefore examined
the effect of GFP–scFv17 expression on mitochondrial STAT3
by isolating mitochondrial and cytosolic fractions from PMA-
stimulated HepG2 cells. The abundance of STAT3 in the mito-
chondrial fraction was affected by neither PMA treatment nor
GFP–scFv17 expression (Fig. 5). The abundance of pSSTAT3
in mitochondria, although relatively low, was increased by PMA
treatment but was not affected by GFP–scFv17 expression (Fig. 5),
suggesting that the mitochondrial localization and serine phosphor-
ylation of STAT3 are independent of its tyrosine-phosphorylation–
related functions.
Effect of Intrabody 17 Expression on Cell Viability and Gene Expression.
Earlier studies with tissue-specific STAT3-deficient mice in-
dicated that in most cell types STAT3 activation leads to sup-
pression of apoptosis, and STAT3 inhibition by stattic or RNAi-
mediated knockdown resulted in decreased cell viability. We
evaluated the effect of GFP–scFv17 expression, stattic, and
RNAi knockdown on the viability of HepG2 cells maintained in
DMEM media supplemented with 10% FBS (Fig. S7). Cell via-
bility was markedly reduced by stattic (∼35% and ∼90% at 2 μM
and 20 μM, respectively) and STAT3 knockdown (∼60%) but
reduced by less than 10% by GFP–scFv17 expression, demon-
strating a differential role of pYSTAT3 in cell survival.
Finally, we identified genes whose expression levels were sig-
nificantly changed by GFP–scFv17 expression or RNAi knockdown
of STAT3, compared with expression in their respective controls in
IL-6–stimulated HepG2 cells (Fig. S8 and Dataset S1). In IL-6–
stimulated HepG2 cells, intrabody expression and STAT3
knockdown affected the mRNA levels of 35 genes and 146
genes, respectively, with 23 genes common to the two groups.
Discussion
STAT3 is a cellular regulator that exhibits functional versatility.
Transcriptional activity of STAT3 independent of pYSTAT3
was demonstrated by mutation of Tyr705 to Phe (Y705F) and ex-
pression of the mutant protein in STAT3-null cells, which resulted
in a more than twofold change in the abundance of >1,000
mRNAs (20). In addition to growth factors and cytokines, STAT3
is activated by oncoproteins and carcinogens. It is capable of in-
ducing cell transformation and tumorigenesis, with STAT3 target
genes being implicated in many processes associated with tumor-
igenesis, including cell proliferation, migration, and invasion as
well as apoptosis, inflammation, and angiogenesis (2). These
effects of STAT3 are mediated in part through its interaction
with many other proteins, with ∼40 such proteins including other
transcriptional factors, cytosolic proteins, and mitochondrial pro-
teins having been identified (3). The functions of pYSTAT3,
pSSTAT3, and USTAT3 thus depend on the extracellular stimu-
lus, cell type, and activation status of the cell, with the role of each
STAT3 species in a given biological process having been difficult
to evaluate.
Approaches based on gene targeting or RNAi, which en-
tirely remove the protein target from a cell, are not in-
formative for evaluation of the function of multiple modified
forms of a protein like STAT3. Expression of mutant forms of
STAT3 such as Y705F or S727A can provide insight but
requires elimination of endogenous STAT3 in the cells under
study. Intrabodies have been developed, especially as therapeutic
agents, for neutralization of the function of target proteins (21). The
utility of this approach was recently highlighted by the preparation
Fig. 4. Effect of GFP–scFv17 expression on PMA-induced pSSTAT3 accumu-
lation and c-Fos gene expression in HepG2 cells. (A and B) HepG2 cells
infected with adenoviruses encoding GFP or GFP–scFv17 (50 pfu per cell)
were incubated with or without PD98059 (50 μM) or PMA (100 ng/mL) for 30
min, after which cell lysates were subjected to immunoblot analysis with
antibodies to the indicated proteins (A) or the relative amount of c-Fos
mRNA in the cells was measured by reverse transcription (RT) and real-time
PCR analysis (B). The mRNA data are means ± SD from three independent
experiments. (C and D) HepG2 cells infected as in A and B were incubated
with or without stattic (100 μM) or PMA (100 ng/mL) for 30 min, after which
cell lysates were subjected to immunoblot analysis (C) or the relative amount
of c-Fos mRNA in the cells was determined (D). The mRNA data are means ±
SD from three independent experiments. **P < 0.01.
Fig. 5. Effect of GFP–scFv17 expression on PMA-induced accumulation of
pSSTAT3 in mitochondria. HepG2 cells infected with adenoviruses encoding
GFP or GFP–scFv17 (50 pfu per cell) were incubated in the absence or pres-
ence of PMA (100 ng/mL) for 30 min, after which mitochondrial (Mito) and
cytosolic (Cyt) fractions were prepared from the cells and subjected to im-
munoblot analysis with antibodies to the indicated proteins. Blots of
pSSTAT3 from three independent experiments are shown. HSP90 and cyto-
chrome oxidase IV (CoxIV) were probed as cytosolic and mitochondrial
markers, respectively.
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of an intrabody that recognizes and stabilizes the conformation of
the inactive form, but not the active form, of protein tyrosine
phosphatase 1B, in an attempt to enhance insulin signaling (22).
Intrabodies are also an attractive option for neutralizing the
function of a particular modified form of a protein that is co-
valently modified at multiple sites, given that it is theoretically
possible to develop an intrabody that binds to an individual
modified site with high specificity, but which spares the function of
others. This possibility has not previously been tested, however.
In the present study, we isolated a phage clone that produces
a Fab (Fab17) that binds specifically to the pYSTAT3 peptide.
The scFv–Fc17 fusion protein derived from the Fab17 clone was
found to bind to the pYSTAT3 peptide with high affinity (Kd =
76 pM) and to react with pYSTAT3 selectively over USTAT3,
pYSTAT1, and other tyrosine-phosphorylated proteins in lysates
of IL-6–stimulated HepG2 cells. The effect of shielding the re-
gion of STAT3 containing phosphorylated Tyr705 was examined
by expressing the intrabody derived from scFv–Fc17 fusion protein
as a GFP fusion protein (GFP–scFv17) in HepG2 cells with the
use of an adenoviral vector. Expression of intrabody 17 blocked
the IL-6–induced translocation of pYSTAT3 to the nucleus as well
as the IL-6–induced production of hepatic APR proteins (hapto-
globin and fibrinogen) that are encoded by genes with promoters
containing the canonical pYSTAT3 binding element (GAS). In
contrast, GFP–scFv17 expression affected neither the accumula-
tion of pSSTAT3 in response to IL-6 or PMA nor PMA-induced
expression of the c-Fos gene. These observations are consistent
with the previous suggestion that pSSTAT3 modulates c-Fos gene
transcription by binding to the SIE located in the promoter region
(17). Given that intrabody expression did not affect the abundance
of pSSTAT3 in mitochondria of PMA-stimulated HepG2 cells,
it also likely does not influence the mitochondrial function of
STAT3, which has been shown to depend on pSSTAT3. Expres-
sion of the intrabody thus selectively blocks signaling downstream
of pYSTAT3 without affecting pSSTAT3-dependent pathways.
This pattern of inhibition differs from that of stattic, which has
been thought to inhibit the function of pYSTAT3 but not that
of pSSTAT3, given that it binds to the SH2 domain of STAT3,
but which in the present study was found to inhibit pSSTAT3
accumulation in cells stimulated with IL-6 or PMA.
The utility of intrabody 17 in vivo was tested by expressing it
in the livers of mice through tail vein injection of GFP–scFv17
adenoviruses followed by further injection of IL-6 or LPS.
Intrabody expression down-regulated LPS- or IL-6–induced in-
duction of APR products in the livers. However, the pattern of
APR down-regulation differed significantly between IL-6– and
LPS-injected mice. Whereas the expression of haptoglobin,
fibrinogen, and SAA1–SAA3 was nearly completely suppressed
in IL-6–injected mice, their expression was inhibited to widely
varying extents (15–95%) in LPS-injected mice. These results pro-
vide an example of how the intrabody can be used in evaluating
the differential impact of pYSTAT3 on the expression of dis-
tinct genes in response to various cytokines and growth factors.
Indeed, an array-based analysis revealed that IL-6–induced gene
expression pattern in GFP–scFv17-expressing HepG2 cells is quite
different from that in STAT3-knockdown HepG2 cells, with the
number of changes being much less in the intrabody-expressing
cells. In another example for the utility of the intrabody, we
showed that the viability of HepG2 cells is not significantly affectd
by GFP–scFv17 expression, whereas the viability is drastically
decreased when STAT3 function was inhibited by stattic or
RNAi-mediated knockdown.
An undesirable effect of the tight binding of GFP–scFv17 to
the tyrosine-phosphorylated site of pYSTAT3 was the accumula-
tion of pYSTAT3 in the absence of external stimulation. The ac-
cumulation of pYSTAT3 was proportional to the level of intrabody
expression. When the level of intrabody expression is high, this
signal-independent accumulation of pYSTAT3 can thus result in
the sequestration of a substantial proportion of STAT3 molecules
in the cytosol and in their uncoupling from the pool sensitive to
signal inputs. Despite this shortcoming, intrabodies are an attrac-
tive option for selective inhibition of the function of one specific
covalently modified form of a protein among multiple such forms,
because of the possibility of developing high-affinity binders and
their intrinsic specificity. For a protein like STAT3, which functions
in several different compartments of the cell, intrabodies can also
be targeted to the compartment of interest. Intrabodies thus have
great potential to increase our understanding of the cellular func-
tions of distinct modified forms of a given protein in living cells.
Materials and Methods
Antibodies to pYSTAT3, pSSTAT3, STAT3, pYSTAT1, STAT1, and to phos-
phorylated or total forms of ERK were obtained from Cell Signaling Tech-
nology; those to haptoglobin, fibrinogen, and β-actin were from Sigma-
Aldrich; and those to phosphotyrosine (4G10) were from Upstate Bio-
technology. Recombinant human IL-6 and antibodies to GFP were obtained
from Abfrontier, and DAPI was from Roche Applied Science.
Details of cell culture, immunoprecipitation, statistical analysis, animal
treatments, and antibody (Fab, scFv–Fc fusion protein, and intrabody) gen-
eration are given in SI Materials and Methods.
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